Download MendeleyDiscovery and Structure-Based Design of Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Interaction.
Ding, J., Liu, L., Chiang, Y.L., Zhao, M., Liu, H., Yang, F., Shen, L., Lin, Y., Deng, H., Gao, J., Sage, D.R., West, L., Llamas, L.A., Hao, X., Kawatkar, S., Li, E., Jain, R.K., Tallarico, J.A., Canham, S.M., Wang, H.(2023) J Med Chem 66: 8310-8323
- PubMed: 37307526
- DOI: https://doi.org/10.1021/acs.jmedchem.3c00787
- Primary Citation of Related Structures:
8G3C, 8G3E - PubMed Abstract:
WDR5 is a critical chromatin cofactor of MYC. WDR5 interacts with MYC through the WBM pocket and is hypothesized to anchor MYC to chromatin through its WIN site. Blocking the interaction of WDR5 and MYC impairs the recruitment of MYC to its target genes and disrupts the oncogenic function of MYC in cancer development, thus providing a promising strategy for the treatment of MYC-dysregulated cancers. Here, we describe the discovery of novel WDR5 WBM pocket antagonists containing a 1-phenyl dihydropyridazinone 3-carboxamide core that was identified from high-throughput screening and subsequent structure-based design. The leading compounds showed sub-micromolar inhibition in the biochemical assay. Among them, compound 12 can disrupt WDR5-MYC interaction in cells and reduce MYC target gene expression. Our work provides useful probes to study WDR5-MYC interaction and its function in cancers, which can also be used as the starting point for further optimization toward drug-like small molecules.
Organizational Affiliation:
Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.
